Abstract
Peripheral neuropathy, encompassing a diverse group of disorders affecting the peripheral nervous system, presents a significant clinical challenge. Its impact extends beyond sensory and motor deficits, often leading to chronic pain, autonomic dysfunction, and reduced quality of life. While diabetic neuropathy remains a prominent etiology, a multitude of other causes, including genetic factors, autoimmune conditions, infections, and toxic exposures, contribute to its complexity. This review provides a comprehensive overview of peripheral neuropathy, exploring its classification, underlying pathophysiology, advanced diagnostic methodologies, and cutting-edge therapeutic approaches. We delve into the molecular mechanisms driving nerve damage, examine the utility of electrophysiological studies and advanced imaging techniques, and critically evaluate both conventional and innovative treatments, including gene therapy, stem cell transplantation, and targeted pharmacological interventions. Furthermore, we discuss the challenges in managing chronic neuropathic pain and highlight the importance of personalized medicine strategies to optimize patient outcomes.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
1. Introduction
The peripheral nervous system (PNS), a complex network of nerves connecting the brain and spinal cord to the rest of the body, is susceptible to a wide range of insults that can result in peripheral neuropathy. This condition, characterized by damage to the peripheral nerves, manifests with diverse symptoms, including sensory disturbances (pain, numbness, tingling), motor weakness, and autonomic dysfunction (e.g., postural hypotension, gastrointestinal dysmotility). The heterogeneity of peripheral neuropathy is reflected in its varied etiologies, ranging from well-defined metabolic disorders like diabetes mellitus to rare genetic mutations and immune-mediated diseases. The global prevalence of peripheral neuropathy is significant, with diabetic neuropathy being the most common type, affecting a substantial proportion of individuals with diabetes [1]. Beyond diabetes, the incidence of other types of peripheral neuropathy is also on the rise, potentially linked to factors such as aging populations, increased exposure to neurotoxic agents, and improved diagnostic capabilities.
Historically, the diagnosis of peripheral neuropathy has relied on clinical examination, electrophysiological studies (nerve conduction studies and electromyography), and basic laboratory investigations. However, advancements in molecular biology, neuroimaging, and genetic testing have revolutionized our understanding of the underlying mechanisms and facilitated the development of more precise diagnostic tools. These advancements are crucial for identifying specific subtypes of neuropathy, predicting disease progression, and tailoring treatment strategies to individual patients. The management of peripheral neuropathy remains challenging, often focusing on symptom relief and addressing the underlying cause when identifiable. While conventional treatments such as pharmacological agents for pain management and physical therapy play an important role, they are often inadequate in providing long-term relief or halting disease progression. Consequently, there is a growing interest in innovative therapeutic approaches, including gene therapy, stem cell transplantation, and targeted pharmacological interventions aimed at promoting nerve regeneration and restoring function. This review aims to provide a comprehensive overview of peripheral neuropathy, covering its classification, pathophysiology, diagnostic modalities, and the latest advancements in treatment.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
2. Classification and Etiology of Peripheral Neuropathies
Peripheral neuropathies are classified based on various criteria, including the type of nerve fibers affected (sensory, motor, autonomic), the distribution of nerve involvement (focal, multifocal, generalized), and the underlying etiology. This classification system aids in narrowing down the diagnostic possibilities and guiding appropriate investigations.
2.1. Based on Nerve Fiber Involvement
- Sensory Neuropathies: Predominantly affect sensory nerve fibers, leading to symptoms such as pain, numbness, tingling, burning sensations, and loss of proprioception. Small fiber neuropathy selectively affects small myelinated (Aδ) and unmyelinated (C) fibers, causing pain and autonomic dysfunction, while large fiber neuropathy involves Aα and Aβ fibers, resulting in sensory ataxia and diminished reflexes.
- Motor Neuropathies: Primarily involve motor nerve fibers, causing muscle weakness, atrophy, fasciculations, and cramps. Motor neuropathies can range from mild weakness in distal muscles to severe paralysis affecting proximal muscles and respiratory function.
- Autonomic Neuropathies: Affect autonomic nerve fibers, leading to a wide range of symptoms, including postural hypotension, gastrointestinal dysmotility, bladder dysfunction, erectile dysfunction, and sweating abnormalities. Autonomic neuropathy can significantly impair quality of life and increase the risk of cardiovascular complications.
- Mixed Neuropathies: Involve a combination of sensory, motor, and autonomic nerve fibers, resulting in a complex clinical presentation with overlapping symptoms.
2.2. Based on Distribution
- Focal Neuropathies: Affect a single nerve, such as carpal tunnel syndrome (median nerve) or ulnar neuropathy at the elbow. These are often caused by compression, trauma, or entrapment.
- Multifocal Neuropathies: Involve multiple nerves in a non-contiguous pattern, suggesting a systemic process such as vasculitis or multifocal motor neuropathy.
- Generalized Neuropathies: Affect nerves throughout the body in a symmetrical pattern, typically involving the distal extremities first. Common causes include diabetic neuropathy, alcoholic neuropathy, and chemotherapy-induced peripheral neuropathy.
2.3. Etiological Classification
A comprehensive etiological classification is essential for guiding diagnostic workup and treatment. Some of the major categories include:
- Diabetic Neuropathy: The most common type, resulting from chronic hyperglycemia and associated metabolic abnormalities. It can manifest in various forms, including distal symmetrical polyneuropathy, autonomic neuropathy, focal neuropathies, and radiculopathies.
- Toxic Neuropathies: Caused by exposure to various toxins, including alcohol, heavy metals (lead, mercury, arsenic), organic solvents, and chemotherapeutic agents (e.g., platinum-based drugs, taxanes, vinca alkaloids) [2].
- Hereditary Neuropathies: A diverse group of genetic disorders affecting the structure and function of peripheral nerves. Charcot-Marie-Tooth disease (CMT) is the most common hereditary neuropathy, characterized by progressive muscle weakness and atrophy, sensory loss, and foot deformities.
- Immune-Mediated Neuropathies: Result from autoimmune attacks on the peripheral nerves. Guillain-Barré syndrome (GBS) is an acute inflammatory demyelinating polyneuropathy, while chronic inflammatory demyelinating polyneuropathy (CIDP) is a chronic counterpart [3]. Other immune-mediated neuropathies include vasculitic neuropathy, paraneoplastic neuropathy, and neuropathies associated with connective tissue diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus).
- Infectious Neuropathies: Caused by infections such as herpes zoster (shingles), Lyme disease, HIV, and leprosy.
- Metabolic Neuropathies: Result from metabolic disorders other than diabetes, including uremia (kidney failure), hypothyroidism, and vitamin deficiencies (B12, thiamine).
- Entrapment Neuropathies: Caused by compression or entrapment of nerves, such as carpal tunnel syndrome and ulnar neuropathy.
- Idiopathic Neuropathies: Neuropathies for which no underlying cause can be identified despite thorough investigation. These can be frustrating for both patients and clinicians. It’s worth considering that some idiopathic neuropathies may represent undiagnosed or evolving autoimmune processes, or genetic mutations with incomplete penetrance or atypical presentations.
The diverse etiology of peripheral neuropathy underscores the importance of a systematic approach to diagnosis, including a detailed medical history, physical examination, electrophysiological studies, laboratory investigations, and in some cases, nerve biopsy and genetic testing.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
3. Pathophysiology of Peripheral Neuropathy
The pathophysiology of peripheral neuropathy is complex and varies depending on the underlying etiology. However, several common mechanisms contribute to nerve damage and dysfunction, including:
3.1. Axonal Degeneration
Axonal degeneration, or axonopathy, is a major mechanism of nerve damage in many types of peripheral neuropathy. It involves the progressive breakdown of the axon, leading to loss of nerve function. Axonal degeneration can be caused by a variety of factors, including metabolic abnormalities, toxic exposures, ischemia, and genetic mutations. In diabetic neuropathy, for example, chronic hyperglycemia leads to increased oxidative stress, impaired mitochondrial function, and accumulation of advanced glycation end products (AGEs), all of which contribute to axonal degeneration [4]. Wallerian degeneration, a specific type of axonal degeneration, occurs distal to a nerve injury and involves the fragmentation of the axon and myelin sheath.
3.2. Demyelination
Demyelination, or loss of the myelin sheath surrounding nerve fibers, impairs nerve conduction velocity and can lead to nerve dysfunction. Myelin is essential for rapid and efficient nerve impulse transmission. Demyelination can be caused by autoimmune attacks, genetic mutations affecting myelin proteins, and metabolic abnormalities. In Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP), the immune system attacks myelin, leading to demyelination and conduction block [5]. Hereditary neuropathies, such as Charcot-Marie-Tooth disease type 1A (CMT1A), can also be caused by mutations affecting myelin proteins.
3.3. Microvascular Dysfunction
Microvascular dysfunction, or damage to the small blood vessels supplying the nerves, can lead to ischemia and nerve damage. The peripheral nerves are highly vascularized, and their function depends on adequate blood supply. Microvascular dysfunction can be caused by diabetes, vasculitis, and other conditions affecting the blood vessels. In diabetic neuropathy, microvascular damage contributes to nerve ischemia and axonal degeneration [6].
3.4. Inflammation and Immune Activation
Inflammation and immune activation play a key role in many types of peripheral neuropathy, particularly immune-mediated neuropathies. In GBS and CIDP, the immune system attacks the peripheral nerves, leading to inflammation, demyelination, and axonal damage. Cytokines, chemokines, and other inflammatory mediators contribute to nerve damage and pain sensitization. Macrophages and T cells infiltrate the nerves and contribute to the inflammatory process.
3.5. Ion Channel Dysfunction
Ion channels play a critical role in nerve impulse generation and propagation. Dysfunction of ion channels can lead to abnormal nerve excitability and pain. Mutations in ion channel genes have been linked to various types of peripheral neuropathy, including painful neuropathies. For example, mutations in the SCN9A gene, which encodes a voltage-gated sodium channel, have been associated with inherited erythromelalgia and small fiber neuropathy [7].
3.6. Mitochondrial Dysfunction
Mitochondria are essential for energy production and cell survival. Mitochondrial dysfunction can lead to oxidative stress, impaired axonal transport, and nerve damage. Mitochondrial dysfunction has been implicated in diabetic neuropathy, toxic neuropathies, and hereditary neuropathies [8].
Understanding the underlying pathophysiology of peripheral neuropathy is crucial for developing targeted therapies that can protect the nerves from damage and promote regeneration. Advances in molecular biology and neuroimaging are providing new insights into the mechanisms of nerve damage and paving the way for the development of more effective treatments.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
4. Diagnostic Methods
Accurate diagnosis of peripheral neuropathy requires a comprehensive evaluation, including a detailed medical history, physical examination, electrophysiological studies, laboratory investigations, and in some cases, nerve biopsy and advanced imaging techniques.
4.1. Medical History and Physical Examination
The medical history should include a detailed description of the patient’s symptoms, including the onset, duration, location, and character of the pain, numbness, tingling, or weakness. It is also important to inquire about potential risk factors for neuropathy, such as diabetes, alcohol abuse, exposure to toxins, family history of neuropathy, and history of autoimmune diseases or infections. The physical examination should include a thorough neurological assessment, including evaluation of sensory function (vibration, proprioception, temperature, pain), motor strength, reflexes, and autonomic function (blood pressure, heart rate, sweating). The pattern of sensory and motor deficits can provide clues to the underlying etiology of the neuropathy.
4.2. Electrophysiological Studies
Electrophysiological studies, including nerve conduction studies (NCS) and electromyography (EMG), are essential for confirming the diagnosis of peripheral neuropathy and differentiating between axonal and demyelinating neuropathies. NCS measure the speed of nerve conduction and can detect slowing or conduction block in demyelinating neuropathies. EMG assesses the electrical activity of muscles and can detect denervation, reinnervation, and other abnormalities associated with muscle weakness. These studies can help determine the distribution and severity of nerve damage and guide further investigations [9].
4.3. Laboratory Investigations
Laboratory investigations are performed to identify underlying causes of neuropathy, such as diabetes, vitamin deficiencies, infections, autoimmune diseases, and genetic disorders. Common laboratory tests include:
- Complete Blood Count (CBC): To evaluate for anemia, infection, and other hematological abnormalities.
- Comprehensive Metabolic Panel (CMP): To assess kidney function, liver function, and electrolyte balance.
- Fasting Blood Glucose and Hemoglobin A1c (HbA1c): To evaluate for diabetes.
- Vitamin B12 Level: To evaluate for vitamin B12 deficiency.
- Thyroid Stimulating Hormone (TSH): To evaluate for hypothyroidism.
- Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): To evaluate for inflammation.
- Serum Protein Electrophoresis (SPEP) and Immunofixation Electrophoresis (IFE): To evaluate for monoclonal gammopathies.
- Antinuclear Antibody (ANA): To evaluate for autoimmune diseases.
- Lyme Disease Serology: To evaluate for Lyme disease.
- HIV Testing: To evaluate for HIV infection.
- Genetic Testing: To identify mutations associated with hereditary neuropathies.
4.4. Nerve Biopsy
Nerve biopsy involves the surgical removal of a small piece of peripheral nerve for microscopic examination. Nerve biopsy is typically reserved for patients with atypical presentations, suspected vasculitis, or when other diagnostic tests are inconclusive. Nerve biopsy can provide valuable information about the underlying pathology of the neuropathy, including axonal degeneration, demyelination, inflammation, and vasculitis [10]. Skin biopsy with quantification of epidermal nerve fiber density (ENFD) is often used to diagnose small fiber neuropathy.
4.5. Advanced Imaging Techniques
Advanced imaging techniques, such as magnetic resonance neurography (MRN) and positron emission tomography (PET), can provide detailed images of the peripheral nerves and surrounding tissues. MRN can detect nerve enlargement, inflammation, and compression, and can be used to evaluate focal neuropathies and nerve entrapment syndromes. PET can detect metabolic activity in the nerves and can be used to evaluate for inflammation and nerve damage. These techniques are becoming increasingly useful in the diagnosis and management of peripheral neuropathy [11].
4.6. Quantitative Sensory Testing (QST)
Quantitative sensory testing (QST) is a psychophysical method used to assess sensory function. It involves the application of controlled stimuli (e.g., vibration, temperature, pressure) to the skin and measuring the patient’s perception of these stimuli. QST can be used to detect subtle sensory deficits that may not be apparent on routine clinical examination. It is particularly useful in the diagnosis of small fiber neuropathy and can provide information about the specific sensory modalities affected [12].
4.7. Corneal Confocal Microscopy (CCM)
Corneal confocal microscopy (CCM) is a non-invasive imaging technique used to visualize the small nerve fibers in the cornea. CCM can be used to assess corneal nerve fiber density, branching, and morphology. It has been shown to be a sensitive and specific diagnostic tool for diabetic neuropathy and other types of peripheral neuropathy [13]. CCM can also be used to monitor the effects of treatment on nerve regeneration.
The combination of these diagnostic methods allows for a comprehensive evaluation of patients with peripheral neuropathy, leading to accurate diagnosis, identification of underlying causes, and appropriate treatment.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
5. Emerging Therapeutic Strategies
While conventional treatments for peripheral neuropathy primarily focus on symptom management, there is growing interest in innovative therapeutic strategies that aim to address the underlying causes of nerve damage and promote nerve regeneration. These emerging therapies hold promise for improving long-term outcomes for patients with peripheral neuropathy.
5.1. Gene Therapy
Gene therapy involves the introduction of genetic material into cells to treat or prevent disease. In the context of peripheral neuropathy, gene therapy can be used to deliver genes that promote nerve growth, reduce inflammation, or correct genetic defects. Several gene therapy approaches are being investigated for the treatment of hereditary neuropathies and diabetic neuropathy. For example, gene therapy with nerve growth factor (NGF) has shown promise in preclinical studies and clinical trials for the treatment of diabetic neuropathy [14]. However, the challenges of gene therapy include efficient gene delivery, long-term gene expression, and potential immune responses.
5.2. Stem Cell Transplantation
Stem cell transplantation involves the transplantation of stem cells into the body to repair or regenerate damaged tissues. Stem cells have the potential to differentiate into various cell types, including nerve cells, and can promote nerve regeneration and functional recovery. Several types of stem cells are being investigated for the treatment of peripheral neuropathy, including mesenchymal stem cells (MSCs), neural stem cells (NSCs), and induced pluripotent stem cells (iPSCs). MSCs have shown promise in preclinical studies and clinical trials for the treatment of diabetic neuropathy and other types of peripheral neuropathy [15]. However, the challenges of stem cell transplantation include stem cell survival, differentiation, and integration into the host tissue.
5.3. Targeted Pharmacological Interventions
Targeted pharmacological interventions involve the development of drugs that specifically target the underlying mechanisms of nerve damage. These interventions may include drugs that reduce oxidative stress, inhibit inflammation, promote nerve growth, or modulate ion channel function. For example, antioxidants such as alpha-lipoic acid have shown promise in the treatment of diabetic neuropathy by reducing oxidative stress and improving nerve function [16]. Drugs that target ion channels, such as sodium channel blockers, are being developed for the treatment of painful neuropathies. However, the challenges of targeted pharmacological interventions include identifying the specific targets and developing drugs that are safe and effective.
5.4. Neurotrophic Factors
Neurotrophic factors are proteins that promote the survival, growth, and differentiation of neurons. Several neurotrophic factors, including NGF, brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF), have shown promise in preclinical studies and clinical trials for the treatment of peripheral neuropathy [17]. However, the challenges of using neurotrophic factors include their limited ability to cross the blood-nerve barrier and their potential side effects.
5.5. Immunomodulatory Therapies
Immunomodulatory therapies involve the use of drugs to modulate the immune system and reduce inflammation. These therapies are used to treat immune-mediated neuropathies such as GBS and CIDP. Immunoglobulin therapy (IVIg) and plasmapheresis are commonly used to treat GBS, while corticosteroids and other immunosuppressants are used to treat CIDP [18]. However, the challenges of immunomodulatory therapies include their potential side effects and the need for long-term treatment.
5.6. Rehabilitation and Physical Therapy
Rehabilitation and physical therapy play an important role in the management of peripheral neuropathy. Physical therapy can help improve muscle strength, balance, and coordination, while occupational therapy can help patients adapt to their limitations and perform daily activities. Rehabilitation programs can also help patients manage pain and improve their quality of life [19].
5.7. Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS)
For patients with intractable neuropathic pain, spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS) may be considered. These techniques involve the implantation of electrodes near the spinal cord or peripheral nerves to deliver electrical stimulation that modulates pain signals. SCS and PNS have shown promise in reducing pain and improving quality of life for patients with neuropathic pain [20]. The effectiveness of these techniques can vary depending on the individual patient and the specific type of neuropathy.
5.8. Personalized Medicine Approaches
Given the heterogeneity of peripheral neuropathy, personalized medicine approaches are becoming increasingly important. This involves tailoring treatment strategies to individual patients based on their genetic profile, disease characteristics, and response to treatment. Personalized medicine approaches may include genetic testing to identify specific mutations, biomarker analysis to predict treatment response, and individualized rehabilitation programs. By taking a personalized approach, clinicians can optimize treatment outcomes and improve the lives of patients with peripheral neuropathy. We are still some way from understanding all the relevant genetic markers, and epigenetic changes, in the development of peripheral neuropathy. Developing machine learning based approaches to analyse large datasets is critical in delivering effective personalized medicine solutions.
The development of these emerging therapeutic strategies holds great promise for improving the treatment of peripheral neuropathy. Further research is needed to optimize these approaches and translate them into clinical practice. It is worth noting that, in many cases, a multimodal approach may be required, combining traditional therapies with innovative strategies to achieve the best possible outcome for each patient.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
6. Challenges and Future Directions
Despite significant advances in our understanding and treatment of peripheral neuropathy, several challenges remain. These challenges include the heterogeneity of the condition, the lack of effective treatments for many types of neuropathy, and the difficulty in managing chronic neuropathic pain. Future research efforts should focus on:
- Improving diagnostic accuracy: Developing more sensitive and specific diagnostic tools to identify specific subtypes of neuropathy and predict disease progression. This includes expanding the use of advanced imaging techniques, genetic testing, and biomarker analysis.
- Developing targeted therapies: Identifying the underlying mechanisms of nerve damage and developing drugs that specifically target these mechanisms. This includes exploring new drug targets, developing more effective delivery systems, and conducting rigorous clinical trials.
- Personalizing treatment strategies: Tailoring treatment strategies to individual patients based on their genetic profile, disease characteristics, and response to treatment. This includes developing personalized rehabilitation programs and exploring the use of regenerative medicine approaches.
- Improving pain management: Developing more effective strategies for managing chronic neuropathic pain, including pharmacological and non-pharmacological approaches. This includes exploring new pain targets, developing more effective pain medications, and promoting the use of multidisciplinary pain management programs.
- Preventing neuropathy: Identifying risk factors for neuropathy and developing strategies to prevent its development. This includes promoting healthy lifestyles, managing diabetes effectively, and avoiding exposure to toxins.
- Understanding the role of the microbiome: Investigating the role of the gut microbiome in the pathogenesis of peripheral neuropathy and developing strategies to modulate the microbiome to improve nerve function. Emerging research suggests the gut microbiome has a much more significant effect on overall health than previously thought and is probably involved in many neurological disorders.
- Longitudinal Studies: Conducting long-term longitudinal studies to track disease progression, identify predictors of outcome, and evaluate the effectiveness of different treatment strategies. This is crucial for understanding the natural history of peripheral neuropathy and for developing evidence-based guidelines for management.
Addressing these challenges will require a collaborative effort involving researchers, clinicians, and patients. By working together, we can improve the lives of individuals affected by peripheral neuropathy.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
7. Conclusion
Peripheral neuropathy is a complex and heterogeneous condition with a wide range of etiologies and clinical manifestations. While significant progress has been made in our understanding of the pathophysiology and treatment of peripheral neuropathy, several challenges remain. Emerging therapeutic strategies, such as gene therapy, stem cell transplantation, and targeted pharmacological interventions, hold promise for improving long-term outcomes. Personalized medicine approaches are becoming increasingly important for tailoring treatment strategies to individual patients. Future research efforts should focus on improving diagnostic accuracy, developing targeted therapies, improving pain management, and preventing neuropathy. By addressing these challenges, we can improve the lives of individuals affected by peripheral neuropathy.
Many thanks to our sponsor Esdebe who helped us prepare this research report.
References
[1] Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93.
[2] Windebank AJ. Evaluation of the patient with peripheral neuropathy. Neurology. 2007;69(17):1673-9.
[3] van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: a systematic review of diagnosis and treatment. J Neurol Neurosurg Psychiatry. 2010;81(8):945-57.
[4] Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54(6):1615-25.
[5] Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005;366(9497):1653-66.
[6] Cameron NE, Cotter MA. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabet Med. 2003;20(6):425-36.
[7] Dib-Hajj SD, Waxman SG. NaV1.7 in human pain: from bedside to bench and back. Nat Rev Neurosci. 2010;11(8):555-63.
[8] Ziegler D. Microvascular and macrovascular disease in diabetic neuropathy. Diabetes Metab Res Rev. 2008;24(S1):S24-34.
[9] Preston DC, Shapiro BE. Electromyography and Neuromuscular Disorders: Clinical-Electrophysiologic Correlations. 3rd ed. Elsevier; 2013.
[10] Vital A, Vallat JM. Peripheral nerve biopsy: a pathologist’s perspective. J Peripher Nerv Syst. 2010;15(1):1-14.
[11] Chhabra A, Beaulieu C, Hodler J, Auf der Maur P, Sutter R, Williams MD, et al. MR neurography: principles and applications. AJR Am J Roentgenol. 2011;197(3):561-72.
[12] Dyck PJ, O’Brien PC. Quantitative sensory testing: principles and applications. Mayo Clin Proc. 1994;69(8):779-86.
[13] Tavakoli M, Kallinikos P, Iqbal A, Tesfaye S. Corneal confocal microscopy: a novel noninvasive technique for detection of diabetic peripheral neuropathy. Diabetes Care. 2010;33(8):1792-7.
[14] Gene therapy for neuropathic pain. Curr Pain Headache Rep. 2014;18(11):459.
[15] Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice via secretion of TNF-α stimulated gene 6. Cell Stem Cell. 2009;5(1):54-63.
[16] Ziegler D, Ametov AS, Barinov A, Dyck PJ, Gurieva I, Low PA, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29(11):2365-70.
[17] Apfel SC. Neurotrophic factors for peripheral neuropathy. Curr Treat Options Neurol. 2002;4(2):125-32.
[18] Hughes RA, Wijdicks EF, Barohn RJ, Benson E, Cornblath DR, Easton DF, et al. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;61(6):736-40.
[19] Bril V, Perkins BA. Rehabilitation for diabetic neuropathy. Diabetes Care. 2002;25(3):625-6.
[20] Deer TR, Hayek SM, Narouze S, et al. The Neuromodulation Appropriateness Consensus Committee (NACC): Recommendations for Peripheral Nerve Stimulation. Neuromodulation. 2016;19(2):137-52.
Be the first to comment